v3.23.3
Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Summary of share-based compensation expense Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2023202220232022
Cost of products sold$9 $8 $38 $33 
Research and development53 47 227 194 
Selling, general and administrative68 71 357 312 
Pre-tax compensation expense130 126 622 539 
Tax benefit(26)(25)(111)(102)
After-tax compensation expense$104 $101 $511 $437 
Summary of quarterly cash dividends The following table summarizes quarterly cash dividends declared during 2023 and 2022:
20232022
Date DeclaredPayment Date
Dividend Per Share
Date Declared
Payment Date
Dividend Per Share
10/26/2302/15/24$1.55 10/28/2202/15/23$1.48 
09/08/2311/15/23$1.48 09/09/2211/15/22$1.41 
06/22/2308/15/23$1.48 06/23/2208/15/22$1.41 
02/16/2305/15/23$1.48 02/17/2205/16/22$1.41 
Summary of changes in balances of each component of accumulated other comprehensive loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2023:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits
Cash flow hedging
activities		Total
Balance as of December 31, 2022$(1,513)$464 $(1,458)$308 $(2,199)
Other comprehensive income (loss) before reclassifications(279)156 43 61 (19)
Net gains reclassified from accumulated other comprehensive loss— (67)(5)(63)(135)
Net current-period other comprehensive income (loss)(279)89 38 (2)(154)
Balance as of September 30, 2023$(1,792)$553 $(1,420)$306 $(2,353)
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2022:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits		Cash flow hedging
activities		Total
Balance as of December 31, 2021$(570)$(91)$(2,546)$308 $(2,899)
Other comprehensive income (loss) before reclassifications(2,043)1,318 6 151 (568)
Net losses (gains) reclassified from accumulated other comprehensive loss— (53)130 (53)24 
Net current-period other comprehensive income (loss)(2,043)1,265 136 98 (544)
Balance as of September 30, 2022$(2,613)$1,174 $(2,410)$406 $(3,443)
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss
The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
Three months ended
September 30,		Nine months ended
September 30,
(in millions) (brackets denote gains)2023202220232022
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)
$(28)$(29)$(85)$(67)
Tax expense6 6 18 14 
Total reclassifications, net of tax$(22)$(23)$(67)$(53)
Pension and post-employment benefits
Amortization of actuarial losses and other(b)
$(2)$55 $(5)$166 
Tax benefit— (12)— (36)
Total reclassifications, net of tax$(2)$43 $(5)$130 
Cash flow hedging activities
Gains on foreign currency forward exchange contracts(c)
$(11)$(21)$(67)$(47)
Gains on treasury rate lock agreements(a)
(6)(6)(18)(18)
Losses on cross-currency swap contracts(d)
14 — 6 — 
Losses on interest rate swap contracts(a)
— — — 3 
Tax expense 2 4 16 9 
Total reclassifications, net of tax$(1)$(23)$(63)$(53)
(a) Amounts are included in interest expense, net (see Note 8).
(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
(c) Amounts are included in cost of products sold (see Note 8).
(d) Amounts are included in net foreign exchange loss (see Note 8).